2seventy bio (TSVT) News Today $4.95 -0.01 (-0.20%) Closing price 04:00 PM EasternExtended Trading$4.96 +0.00 (+0.10%) As of 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period 2seventy bio Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 25 at 4:05 PM | businesswire.com2seventy bio (NASDAQ:TSVT) Receives "Sell (E+)" Rating from Weiss RatingsMarch 24 at 2:51 AM | americanbankingnews.com2seventy bio's (TSVT) Sell (E+) Rating Reiterated at Weiss RatingsWeiss Ratings reissued a "sell (e+)" rating on shares of 2seventy bio in a report on Saturday.March 24 at 2:12 AM | marketbeat.com2seventy bio, Inc. (NASDAQ:TSVT) COO Jessica Snow Sells 2,298 Shares2seventy bio, Inc. (NASDAQ:TSVT - Get Free Report) COO Jessica Snow sold 2,298 shares of the business's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $4.95, for a total transaction of $11,375.10. Following the completion of the sale, the chief operating officer now directly owns 254,193 shares of the company's stock, valued at $1,258,255.35. This represents a 0.90 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.March 20, 2025 | marketbeat.comInsider Selling: 2seventy bio, Inc. (NASDAQ:TSVT) CFO Sells 2,592 Shares of Stock2seventy bio, Inc. (NASDAQ:TSVT - Get Free Report) CFO Victoria Eatwell sold 2,592 shares of the business's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $4.95, for a total value of $12,830.40. Following the completion of the sale, the chief financial officer now owns 444,387 shares in the company, valued at approximately $2,199,715.65. The trade was a 0.58 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.March 20, 2025 | marketbeat.comWilliam D. Baird III Sells 5,092 Shares of 2seventy bio, Inc. (NASDAQ:TSVT) Stock2seventy bio, Inc. (NASDAQ:TSVT - Get Free Report) CEO William D. Baird III sold 5,092 shares of the stock in a transaction on Monday, March 17th. The stock was sold at an average price of $4.95, for a total value of $25,205.40. Following the sale, the chief executive officer now owns 1,121,034 shares in the company, valued at $5,549,118.30. The trade was a 0.45 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.March 20, 2025 | marketbeat.comJessica Snow Sells 2,298 Shares of 2seventy bio, Inc. (NASDAQ:TSVT) StockMarch 20, 2025 | insidertrades.comMonimus Capital Management LP Invests $775,000 in 2seventy bio, Inc. (NASDAQ:TSVT)Monimus Capital Management LP bought a new position in 2seventy bio, Inc. (NASDAQ:TSVT - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 263,644 shares of the company's stock, valued at approximatMarch 16, 2025 | marketbeat.comMorgan Stanley Lowers 2seventy bio (NASDAQ:TSVT) Price Target to $5.00Morgan Stanley decreased their target price on shares of 2seventy bio from $6.00 to $5.00 and set an "equal weight" rating on the stock in a research note on Friday.March 15, 2025 | marketbeat.com2seventy bio (NASDAQ:TSVT) Price Target Lowered to $5.00 at Morgan StanleyMarch 15, 2025 | americanbankingnews.comInsider Selling: 2seventy bio, Inc. (NASDAQ:TSVT) Major Shareholder Sells 5,142,111 Shares of Stock2seventy bio, Inc. (NASDAQ:TSVT - Get Free Report) major shareholder Global Healthcare Master Kynam sold 5,142,111 shares of the firm's stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $4.93, for a total value of $25,350,607.23. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Large shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.March 14, 2025 | marketbeat.com2seventy Bio price target lowered to $5 from $6 at Morgan StanleyMarch 14, 2025 | markets.businessinsider.com2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVTMarch 14, 2025 | businesswire.com2seventy bio, Inc. (NASDAQ:TSVT) Major Shareholder Sells $25,350,607.23 in StockMarch 14, 2025 | insidertrades.com2seventy bio (NASDAQ:TSVT) Downgraded to Hold Rating by Leerink PartnrsLeerink Partnrs downgraded 2seventy bio from a "strong-buy" rating to a "hold" rating in a research note on Tuesday.March 14, 2025 | marketbeat.comBiotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & MoreMarch 13, 2025 | msn.com$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of 2seventy bio, Inc. - TSVTMarch 12, 2025 | prnewswire.com2seventy bio (NASDAQ:TSVT) Given Market Perform Rating at Leerink PartnersLeerink Partners reissued a "market perform" rating and issued a $5.00 target price (down previously from $9.00) on shares of 2seventy bio in a report on Tuesday.March 12, 2025 | marketbeat.comShareholder Alert: The Ademi Firm investigates whether 2seventy bio, Inc. is obtaining a Fair Price for its Public ShareholdersMarch 11, 2025 | businesswire.comTSVT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of 2seventy bio, Inc. Is Fair to ShareholdersMarch 11, 2025 | tmcnet.com2seventy Bio to be acquired by Bristol Myers for $5.00 per share in cashMarch 11, 2025 | markets.businessinsider.comALERT: Rowley Law PLLC is Investigating Proposed Acquisition of 2seventy bio, Inc.March 11, 2025 | prnewswire.com1,254,827 Shares in 2seventy bio, Inc. (NASDAQ:TSVT) Acquired by Regeneron Pharmaceuticals Inc.Regeneron Pharmaceuticals Inc. acquired a new position in 2seventy bio, Inc. (NASDAQ:TSVT - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 1,254,827 shares of the company's stock, vMarch 11, 2025 | marketbeat.com2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers SquibbMarch 10, 2025 | businesswire.com2seventy bio, Inc. (NASDAQ:TSVT) Given Consensus Recommendation of "Moderate Buy" by Brokerages2seventy bio, Inc. (NASDAQ:TSVT - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the six analysts that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating, two have assigned a buMarch 10, 2025 | marketbeat.com2seventy bio (NASDAQ:TSVT) Receives Sell (D-) Rating from Weiss RatingsWeiss Ratings reissued a "sell (d-)" rating on shares of 2seventy bio in a research report on Friday.March 8, 2025 | marketbeat.com2seventy bio to Participate in the 2025 TD Cowen Healthcare ConferenceFebruary 25, 2025 | finance.yahoo.com2seventy bio to Participate in the 2025 TD Cowen Healthcare ConferenceFebruary 25, 2025 | businesswire.com2seventy bio (TSVT) Projected to Post Earnings on Tuesday2seventy bio (NASDAQ:TSVT) will be releasing earnings before the market opens on Tuesday, March 4.February 25, 2025 | marketbeat.comWeiss Ratings Reiterates "Sell (D-)" Rating for 2seventy bio (NASDAQ:TSVT)Weiss Ratings reaffirmed a "sell (d-)" rating on shares of 2seventy bio in a research note on Wednesday.February 20, 2025 | marketbeat.com2seventy bio, Inc. (NASDAQ:TSVT) Given Average Rating of "Moderate Buy" by Brokerages2seventy bio, Inc. (NASDAQ:TSVT - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the six ratings firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold ratinFebruary 13, 2025 | marketbeat.comCiti cuts 2Seventy Bio stock target to $9, maintains Buy ratingFebruary 6, 2025 | msn.com2seventy bio Reports Preliminary* Full-Year U.S. Abecma Sales and Select Financial ResultsFebruary 6, 2025 | finance.yahoo.com2seventy bio reports $242 million in 2024 Abecma salesFebruary 6, 2025 | msn.com2seventy bio's (TSVT) "Sell (E+)" Rating Reaffirmed at Weiss RatingsWeiss Ratings reiterated a "sell (e+)" rating on shares of 2seventy bio in a research report on Saturday.February 4, 2025 | marketbeat.com2seventy bio, Inc. (NASDAQ:TSVT) Receives Consensus Rating of "Moderate Buy" from AnalystsShares of 2seventy bio, Inc. (NASDAQ:TSVT - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the nine research firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, three have assigned a holdJanuary 19, 2025 | marketbeat.comWeiss Ratings Reaffirms "Sell (E+)" Rating for 2seventy bio (NASDAQ:TSVT)Weiss Ratings reissued a "sell (e+)" rating on shares of 2seventy bio in a research note on Saturday.January 19, 2025 | marketbeat.comBarclays PLC Reduces Holdings in 2seventy bio, Inc. (NASDAQ:TSVT)Barclays PLC reduced its stake in 2seventy bio, Inc. (NASDAQ:TSVT - Free Report) by 62.1% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 80,594 shares of the company's stock after selling 132,019 shares during the quarter. BarclJanuary 19, 2025 | marketbeat.com2seventy bio: Buy Rating Amidst Challenges and Growth Potential in BCMA CAR-T TherapyDecember 6, 2024 | markets.businessinsider.comLeerink Partnrs Reduces Earnings Estimates for 2seventy bio2seventy bio, Inc. (NASDAQ:TSVT - Free Report) - Analysts at Leerink Partnrs dropped their FY2024 earnings per share estimates for 2seventy bio in a report released on Wednesday, December 4th. Leerink Partnrs analyst D. Graybosch now anticipates that the company will post earnings per share of ($December 6, 2024 | marketbeat.comWestern Standard LLC Takes Position in 2seventy bio, Inc. (NASDAQ:TSVT)Western Standard LLC acquired a new position in 2seventy bio, Inc. (NASDAQ:TSVT - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 285,931 shares of the company's stock, valued at apprDecember 6, 2024 | marketbeat.com2seventy bio (TSVT) Gets a Hold from Morgan StanleyDecember 6, 2024 | markets.businessinsider.com2seventy bio, Inc. (NASDAQ:TSVT) Shares Sold by Healthcare of Ontario Pension Plan Trust FundHealthcare of Ontario Pension Plan Trust Fund reduced its stake in 2seventy bio, Inc. (NASDAQ:TSVT - Free Report) by 59.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 590,000 shares of the company's stock aDecember 1, 2024 | marketbeat.comBBR Partners LLC Has $850,000 Position in 2seventy bio, Inc. (NASDAQ:TSVT)BBR Partners LLC raised its position in 2seventy bio, Inc. (NASDAQ:TSVT - Free Report) by 620.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 180,000 shares of the company's stock after purchasing an additional 155,000November 28, 2024 | marketbeat.comMarcela V. Maus Sells 3,900 Shares of 2seventy bio, Inc. (NASDAQ:TSVT) StockNovember 21, 2024 | insidertrades.comUS$8.25: That's What Analysts Think 2seventy bio, Inc. (NASDAQ:TSVT) Is Worth After Its Latest ResultsNovember 15, 2024 | finance.yahoo.com2seventy bio Reports Strong Growth in Abecma SalesNovember 15, 2024 | markets.businessinsider.comTD Cowen Reaffirms Their Hold Rating on 2seventy bio (TSVT)November 15, 2024 | markets.businessinsider.com2seventy Bio's Losses Narrow, Sales DipNovember 13, 2024 | fool.com2seventy bio Inc (TSVT) Q3 2024 Earnings Call Highlights: Strong Abecma Growth and Strategic ...November 13, 2024 | finance.yahoo.com Remove Ads Get 2seventy bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TSVT and its competitors with MarketBeat's FREE daily newsletter. Email Address TSVT Media Mentions By Week TSVT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TSVT News Sentiment▼0.500.68▲Average Medical News Sentiment TSVT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TSVT Articles This Week▼132▲TSVT Articles Average Week Remove Ads Get 2seventy bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TSVT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Intellia Therapeutics News Today Arcus Biosciences News Today Vir Biotechnology News Today Rocket Pharmaceuticals News Today Collegium Pharmaceutical News Today Xencor News Today Replimune Group News Today Phibro Animal Health News Today Day One Biopharmaceuticals News Today Zymeworks News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TSVT) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 2seventy bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 2seventy bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TSVT Stock Free TSVT Stock Alerts